Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2025
Characteristics of Black Adults Who Never Achieved 24-Hours of Abstinence in a Smoking Cessation Trial: Implications for Improving Treatment Response.
Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionMaximizing early treatment response is an important strategy for long-term abstinence, yet little is known about individuals who never achieve any period of abstinence. Improving early treatment response is critical for Black adults who smoke (AWS) who bear a disproportionate share of tobacco-related mortality.
methodsSecondary data analysis of a randomized clinical trial among Black AWS (N = 392) interested in quitting smoking. Participants received 18 weeks of pharmacotherapy and smoking cessation counseling. This investigation quantified the proportion of participants who never achieved 24-hour abstinence through week 2 (W2). Best subsets logistic regression identified baseline and non-baseline factors contributing to never achieving 24-hour abstinence.
results135 participants (36.2%) did not achieve 24-hour abstinence by W2 despite good adherence with nicotine patch (73.9% had > 80% compliance). Of those, 56.4% and 47.8% still did not achieve 24-hour abstinence at W6 and W12, respectively. Baseline financial strain, higher baseline cotinine and smoking more CPD at W2 increased odds of never achieving 24-hour abstinence while greater cessation self-efficacy and more positive beliefs about study medication at W2 decreased odds of never achieving 24-hours abstinence.
conclusionsA substantial proportion of individuals who were motivated to quit smoking and received gold-standard treatment (i.e., pharmacotherapy and counseling) never achieved a period of 24 hours of abstinence. Findings highlight financial strain, nicotine dependence, early self-efficacy challenges, and medication experience as targets for improving abstinence among those at high risk for early treatment failure. By characterizing a subset within a larger population at-risk of continued smoking, the study presents opportunities to consider contributors to treatment success. IMPLICATIONS: Individuals who do not experience success with quitting early in treatment rarely go on to achieve long-term abstinence, yet the majority of interventions fail to address challenges among this high-risk subgroup. Findings suggest a need for interventions that consider the psychological impact of unmet social needs associated with financial strain, address low cessation self-efficacy, and early experiences with smoking cessation pharmacotherapy as approaches for bolstering treatment efficacy. Two possible evidence-based interventions for addressing these factors are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.